Rainer Blair, Danaher CEO (Photo by Lintao Zhang/Getty Images)
October 25, 2023 07:20 AM EDT
China
Outsourcing
Pharma

Dana­her’s third-quar­ter rev­enue from biotech ser­vices down 19% amid slow­down in Chi­na, US

Ayisha Sharma

News Reporter

An an­tic­i­pat­ed re­duc­tion in biotech sales con­tributed to Dana­her’s third-quar­ter per­for­mance drop­ping rel­a­tive to last year, the com­pa­ny re­vealed Tues­day. This is in the midst …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Bio­phar­ma be­gins to con­tem­plate an RFK Jr.-in­flu­enced FDA if Trump wins

Pfiz­er shares new de­tails on obe­si­ty pipeline, hints at ‘oth­er op­por­tu­ni­ties’

GSK buys au­toim­mune T cell en­gager for $300M up­front from Chim­a­gen

No­var­tis takes $800M Mor­phoSys write­down mere months af­ter clos­ing ac­qui­si­tion

No­var­tis high­lights over­all M&A track record fol­low­ing Mor­phoSys im­pair­ment

Fol­low­ing March in­spec­tion, No­vo Nordisk's semaglu­tide man­u­fac­tur­ing fa­cil­i­ty cit­ed by FDA

A service from the Financial Times